Key result
Incident aortic stenosis is linked to ~2.6-fold higher all-cause mortality versus matched controls.
Why the study?
In aortic stenosis, it is unclear how improved diagnosis, earlier referral, and broader intervention indications translate into survival benefit. Furthermore, detailed knowledge regarding major causes of death, place of death, and autopsy verification rates in AS is limited.
Cohort (n=432,848)
Yes
In a large nationwide Swedish cohort, individuals with incident aortic stenosis faced a more than two-fold higher risk of all-cause mortality and a more than three-fold higher risk of cardiovascular mortality compared with matched controls, despite adjustments for valve interventions.
Background Aortic stenosis (AS) is the most common valvulopathy requiring intervention (1, 2), an increasingly important cause of morbidity and mortality in Sweden. While progress has been made in improved diagnosis, earlier referral and broader indications for valve interventions (3), it is unclear how this translates into survival benefit. In addition, detailed knowledge of the major causes of death, place of death, and rates of autopsy verification in AS is limited. Purpose To quantify long-term all-cause and cardiovascular mortality in individuals with incident AS compared with matched population controls, and to characterize detailed cause-of-death patterns. Methods All individuals aged ≥50 years with incident aortic stenosis were identified from the Swedish National Patient Register using ICD codes. Individuals with AS were matched on sex and year of birth to individuals without valvulopathies. Baseline comorbidities, aortic valve interventions (time-updated), socioeconomic variables, vital status and causes of death were identified through linkage with other registers. The primary outcomes were all-cause mortality and cardiovascular mortality. Secondary outcomes included detailed cause-specific mortality, place of death, and autopsy verification rates. Survival was assessed using Kaplan–Meier estimates and using Cox proportional hazards models. Results Among the 432 848 individuals (83 041 with AS and 349 807 without), the mean age was 76 years. Individuals with AS were older than comparators and had more comorbidities. During a mean follow-up time of 6,6 years, 192 467 (44.5%) deaths were recorded. Crude all-cause and cardiovascular mortality rates were substantially higher among individuals with AS (Figure 1). After multivariable adjustment for age, sex, comorbidities, and time-updated valve interventions, AS was associated with a more than two-fold increased risk of all-cause mortality (HR 2.63, 95% CI 2.60–2.67) and a more than three-fold of cardiovascular mortality (HR 3.59, 95% CI 3.52–3.66). Older age, male sex, and higher comorbidity burden were independently associated with increased mortality, while aortic valve intervention was associated with improved survival. Cardiovascular disease was the leading cause of death in both groups, followed by malignancy, while in the third position were respiratory disease (for AS individuals) and psychiatric disorders (for comparators) (Figure 2). Individuals with AS were more likely to die in hospital and underwent autopsy more frequently. Conclusions Individuals with aortic stenosis remain at increased risk of all-cause and cardiovascular mortality compared with general population. Although cardiovascular disease and malignancy were the leading causes of death in both groups, individuals with AS exhibited a substantially higher proportion of cardiovascular and respiratory deaths, and more frequent in-hospital death, indicating a persistent prognostic burden.Figure 1Figure 2
No takes yet. Share an insight, caveat, or question.
Kontogeorgos et al. (2026) conducted a cohort in Incident aortic stenosis (n=432,848). Incident aortic stenosis vs. Matched population controls without valvulopathies was evaluated on All-cause mortality and cardiovascular mortality (HR 2.63, 95% CI 2.60-2.67). Incident aortic stenosis was associated with higher all-cause (HR 2.63, 95% CI 2.60-2.67) and cardiovascular mortality (HR 3.59, 95% CI 3.52-3.66) vs matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: